Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 8/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016168 | 0.86 | ATM (0.45) | LMNA | |
| SCHEMBL4017274 | 0.85 | PPARD (0.39) | ROCK2MCHR1PPARDPARP10PARP15 | |
| SCHEMBL4018723 | 0.80 | OPRM1 (0.41) | ROCK2TTKMCHR1PARP10PARP15 | |
| SCHEMBL4018970 | 0.78 | CARM1 (0.42) | PPARDOPRM1OPRD1OPRK1LMNA | |
| SCHEMBL4019647 | 0.77 | FPR2 (0.38) | ROCK2PPARDPARP10OPRM1OPRD1 | |
| SCHEMBL4019651 | 0.77 | PARP10 (0.40) | ROCK2PARP10PARP15OPRM1OPRD1 | |
| SCHEMBL4024256 | 0.76 | DRD4 (0.46) | PPARDOPRM1OPRD1OPRK1LMNA | |
| SCHEMBL4017097 | 0.76 | PPARD (0.42) | ROCK2PPARDLMNAHTT | |
| SCHEMBL4024269 | 0.76 | LMNA (0.42) | ROCK2PPARDOPRM1OPRD1OPRK1 | |
| SCHEMBL13622917 | 0.75 | MAOB (0.44) | MCHR1PPARDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | ROCK2 2928/4885TTK 4685/4885ALDH2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.